Dr Michel Sadelain AACR

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016
ECCO 2013 Poster Hall

Dr Oliver Sartor shares his thoughts on Prostate Cancer data at ECCO 2013

Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.

September 30, 2013

ECCO Day 3: Update on alectinib, PD-L1, PI3K and MEK

Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours

September 30, 2013
BMN 673 waterfall plot in BRCA1/2 breast cancer

ECCO Highlights Day 2: Breast and Ovarian Cancer

The latest data on BioMarin's PARP inhibitor BMN 673 in breast and ovarian cancer from ECCO 2013

September 29, 2013
ECCO 2013 Bikes

ECCO 2013: AZD9291 shows early promise in T790M NSCLC

Promising preliminary phase 1 data for AstraZeneca’s AZD9291 in T790M+ NSCLC presented today at the European Cancer Congress (ECCO 2013) is good news for lung cancer patients.

September 29, 2013
ECCO 2013 Amsterdam

ECCO 2013: Is ODM-201 too late to the prostate cancer party?

At ECCO 2013 in Amsterdam, positive data was presented from the phase 1/2 clinical trial for ODM-201 (Orion) a second generation AR antagonist. In contrast the data for ASP9521 (Astellas), a novel androgen biosynthesis inhibitor was negative.

September 29, 2013
Source: Ariad

ECCO 2013 Notes from the Road – Day 1

Update on ipilimumab, AP26113, T-DM1, everolimus and others from Day 1 at the 2013 ECCO meeting in Amsterdam.

September 28, 2013
photo credit: Claudio.Ar via photopin cc

Preview of key ALK lung cancer abstracts at ECCO 2013

Review of the key abstracts in EML4-ALK lung cancer abstracts being presented at ECCO 2013 in Amsterdam.

September 23, 2013
ECCO 2013 Conference Amsterdam

A top line look at the PD-1 and PD-L1 abstracts at ECCO 2013

A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.

September 19, 2013
With permission from Dr Wolchok

How new approaches in targeted immunotherapy with anti-PD-1 and PD-L1 may change cancer research

Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.

September 18, 2013

Preview of 2013 European Cancer Congress in Amsterdam

2013 European Cancer Congress organized by ECCO takes place in Amsterdam from September 27 to October 1st. This is a preview of some of the abstracts to watch out for at the meeting.

September 16, 2013